Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

124 results about "Synucleinopathies" patented technology

Synucleinopathies (also called α-Synucleinopathies) are neurodegenerative diseases characterised by the abnormal accumulation of aggregates of alpha-synuclein protein in neurons, nerve fibres or glial cells. There are three main types of synucleinopathy: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Other rare disorders, such as various neuroaxonal dystrophies, also have α-synuclein pathologies.

Compositions and methods for treating synucleinopathies

The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and / or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.
Owner:H LUNDBECK AS +1

Compositions and methods for treating synucleinopathies

The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and / or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.
Owner:H LUNDBECK AS +1

Compositions and methods for treating synucleinopathies

The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and / or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.
Owner:H LUNDBECK AS +1

SiRNA compositions and methods targeting alpha-synuclein nucleic acids

The present application relates to single-stranded or double-stranded interfering RNA molecules (e.g., siRNAs) that target the alpha synuclein (SNCA) gene. The interfering RNA molecule may contain a specific pattern of nucleoside modification and inter-nucleoside linkage modification as a pharmaceutical composition comprising the interfering RNA molecule. The siRNA molecule may be a branched siRNA molecule, such as a two-branched, three-branched or four-branched siRNA molecule. The disclosed siRNA molecules may also be characterized by a 5 '-phosphorus stabilizing moiety and / or a hydrophobic moiety. In addition, the present disclosure provides methods for delivering siRNA molecules of the present disclosure to a subject, such as the central nervous system of a subject identified as having synucleinopathies.
Owner:ATALANTA THERAPEUTICS INC

Serological assays for parkinson's disease

The present invention provides improved and minimally invasive biomarker-based diagnostics for synucleinopathies (e.g., Parkinson's disease (PD)). The invention further provides assays and methods for analysis of biological samples, for the evaluation and determination of characteristics pertaining to pathological processes associated with α-synuclein, and to methods for determining the suitability of analytical agents for diagnosis of synucleinopathies. More specifically, the invention in embodiments thereof provides improved methods comprising specific detection and quantification of α-synuclein-based biomarkers from low volumes of biological samples.
Owner:NEURODEX INC

Agents, uses and methods for treatment of synucleinopathy

To provide novel monoclonal anti-α-synuclein antibodies.SOLUTION: Disclosed is an antibody that can bind to the toxic α-synuclein fragment 1 to 119 / 122 and neutralize this truncated form of α-synuclein. The antibody can be used to treat synucleinopathies such as Parkinson's disease (including idiopathic and hereditary Parkinson's disease), diffuse Lewy body disease (DLBD), Lewy body variant Alzheimer's disease (LBV), combined Alzheimer's and Parkinson's disease, pure autonomic failure, and multiple system atrophy.SELECTED DRAWING: None
Owner:H LUNDBECK AS

Application of seven interactive genes in preparation of kit for predicting transformation of iRBD to synucleinopathies

The invention relates to the field of medical diagnosis, in particular to seven interactive genes, a prediction system for predicting transformation of primary fast-moving eye sleep disorder (iRBD) to synucleinopathies and application of the seven interactive genes to preparation of a kit for predicting transformation of the iRBD to the synucleinopathies. According to the prediction system, the median of the model value is innovatively adopted as a critical point to distinguish the transformation risk, so that the prediction accuracy and reliability are remarkably improved. Compared with an existing prediction method, the method shows higher specificity and sensitivity, so that the system can accurately identify high-risk patient groups in the early stage of the disease course. The method has convenience and high efficiency in clinical application. By applying the prediction system to preparation of the kit, the clinical detection process is simplified, so that a doctor can quickly perform detection and obtain a result, and more effective management and treatment on an iRBD patient are realized.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating α-synucleinopathies, tauopathies, and other disorders

To provide methods of treating or suppressing a disorder selected from the group consisting of α-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.SOLUTION: There are disclosed methods of treating or suppressing a disorder selected from the group consisting of α-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.SELECTED DRAWING: None
Owner:PTC THERAPEUTICS INC

SNCA-targeting sirna compositions for treating SNCA-associated disease

The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a SNCA gene, particularly in a CNS tissue, as well as methods of inhibiting expression of a SNCA gene and methods of treating subjects having a SNCA-associated neurodegenerative disease or disorder, e.g., Parkinson's Disease (PD), multiple system atrophy (MSA), Lewy body dementia (LBD), among other synucleinopathies, using such dsRNAi agents and compositions.
Owner:ALNYLAM PHARMACEUTICALS INC

Compositions and methods for treating synucleinopathies

Dosage regimens of anti-α-synuclein antibodies are provided. These dosage regimens find use in the treatment of synucleinopathies such as Parkinson's disease (PD), Parkinson's Disease Dementia (PDD), dementia with Lewy bodies (DLB), Lewy body variant of Alzheimer's disease (LBVAD), pure autonomic failure (PAF), multiple system atrophy (MSA), and neurodegeneration with brain iron accumulation type-1 (NBIA-I).
Owner:BIOGEN INT NEUROSCI

Alpha-synuclein single domain antibodies

The present disclosure is directed to single domain antibodies that bind to α-synuclein and the use of these antibodies for the treatment and diagnosis of α-synucleinopathies. The present disclosure is also directed to polynucleotides encoding the α-synuclein single domain antibodies, therapeutic vectors comprising these polynucleotides and methods of administering these therapeutic vectors for the treatment of α-synucleinopathies.
Owner:NEW YORK UNIV

Gene therapy for treating synucleinopathies

The present invention relates to a gene therapy for treating synucleinopathies. The present invention provides a novel α-Syn peptide variant and inhibits the formation of amyloid fibrils and degrades α-Syn aggregates, thereby exhibiting excellent preventive, ameliorative, and therapeutic effects on synucleinopathies.
Owner:ABRAIN

SNCA-targeting sirna compositions for treating SNCA-associated disease

The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a SNCA gene, particularly in a CNS tissue, as well as methods of inhibiting expression of a SNCA gene and methods of treating subjects having a SNCA-associated neurodegenerative disease or disorder, e.g., Parkinson's Disease (PD), multiple system atrophy (MSA), Lewy body dementia (LBD), among other synucleinopathies, using such dsRNAi agents and compositions.
Owner:ALNYLAM PHARMACEUTICALS INC

Method for detecting misfolded alpha-synuclein protein in biological samples to determine the presence of synucleinopathies in an individual

The invention relates to a method for detecting misfolded alpha-synuclein protein in a biological sample to determine the presence of synucleinopathies in an individual. The method provided by the present invention can also be used for differential diagnosis of Lewy fold synucleinopathies from MSA synucleinopathies as well as for monitoring of the disease progression in individuals. Moreover, a kit for detecting misfolded αSyn protein in biological samples is provided.
Owner:MODAG GMBH

Substituted fused pyrimidine compounds and uses thereof

ActiveUS12291533B2Nervous disorderOrganic chemistryDementia with Lewy bodiesDisease
Disclosed are new small molecules having a substituted pyrimidine or substituted fused pyrimidine core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including Gaucher's disease and neurological diseases and disorders such as genetic and sporadic synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy associated with aberrant glucocerebrosidase activity. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.
Owner:NORTHWESTERN UNIV

Alpha-synuclein detection assay and method for diagnosing alpha-synucleinopathies

A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample.
Owner:THE UNIV COURT OF THE UNIV OF EDINBURGH

Multiepitope vaccine for the treatment of ALZHEIMER'S disease

The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ, Abeta) peptide, a tau peptide, and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and tau and an alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds and an alpha-synuclein synucleinopathies in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and amyloid-beta and an alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide and an alpha-synuclein peptide.
Owner:OTHAIR PROTHENA LTD

Compositions and methods for treating synucleinopathies

The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and / or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.
Owner:H LUNDBECK AS +1

NK1-antagonist combination and method for treating synucleinopathies

PendingEP4461362A3Nervous disorderOrganic chemistryPramipexole dihydrochloride monohydrateSynucleinopathies
The present invention describes the use of a NK1-antagonist, in combination with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to facilitate the treatment of a patient suffering from a synucleinopathy by enabling a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose to act without the typical adverse effects caused by pramipexole dihydrochloride monohydrate when administered alone.
Owner:ALTO NEUROSCIENCE INC

PROTACs AND HyT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS

The present invention relates to the finding of the role of DCAF15 in protein aggregation. The present invention further relates to PROTACs and HyT-PD molecules for targeted protein degradation (TPD) of DCAF15 as well as their use as a medicament for the treatment of amyloidosis, in particular their use in the treatment of synucleinopathies.
Owner:KRFTENS BEKMPELSE +1

Methods and compositions related to evolving botulinum toxin proteases for targeted substrate specificities

PCT designated stageWO2026178072A1Protein targetConjugated protein
This invention provides libraries of Botulinum neurotoxin A (BoNT / A) protease variants for stepwise evolution of the enzyme to generate BoNT / A variants that can specifically cleave a desired cleavage site in a target protein. Related methods for performing stepwise evolution of BoNT / A with the BoNT / A variant libraries and simultaneous stepwise evolution of a desired substrate sequence in a target protein are also provided by the disclosure. Additionally provided in the disclosure are specifically evolved BoNT / A variant enzymes and conjugate proteins that specifically degrade intrinsically disordered proteins (IDPs) that are involved in human deceases, e.g., a-Synuclein. Polynucleotide sequences encoding the engineered BoNT / A proteases, expression vectors and related pharmaceutical compositions are also provided in this disclosure. Further encompassed by the invention are therapeutic methods that utilize the engineered BoNT / A enzymes in the treatment of various synucleinopathies.
Owner:THE SCRIPPS RES INST

Application of substance for detecting high signal of dorsal-lateral nigra in preparation of product for detecting alpha-synucleinopathy

PendingCN119279506AHelps with system managementreduce twistMedical data miningMedical automated diagnosisDiagnostic modalitiesRapid eye movement sleep behaviour disorder
The invention relates to an application of a substance for detecting high signals of dorsal-lateral nigra in preparation of a product for detecting alpha-synucleinopathies. The Parkinson's disease and rapid eye movement sleep behavior disorder diagnosis system is constructed based on an analysis strategy of magnetic sensitive weighted imaging, the diagnosis system can be effectively applied to auxiliary diagnosis, the diagnosis sensitivity of the Parkinson's disease is 93.8%, the specificity is 96.7%, the diagnosis sensitivity of the rapid eye movement sleep behavior disorder is 66.7%, and the diagnosis sensitivity of the rapid eye movement sleep behavior disorder is 96.7%. The kit has the advantages that the sensitivity is high, the specificity is 98.0%, the rapid eye movement sleep behavior disorder or the Parkinson's disease can be subjected to etiological typing, systematic management and effective prevention of patients are facilitated, the clinical diagnosis uncertainty of the Parkinson's disease is remarkably reduced through the diagnosis mode, early screening diagnosis is promoted, and the clinical diagnosis and treatment level is improved.
Owner:TIANJIN KINGMED CENT FOR CLINICAL CO LTD

Gene therapies for lysosomal disorders

ActiveUS12797486B2LysosomeSynucleinopathies
The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as Parkinson's disease and Gaucher disease. The disclosure provides methods of treating Gaucher disease, Parkinson's disease or other synucleinopathies by administering expression constructs comprising a transgene encoding beta-glucocerebrosidase, an inhibitory RNA targeting alpha-Synuclein, or a combination of the foregoing to a subject in need thereof.
Owner:PREVAIL THERAPEUTICS INC

NK1-antagonist combination and method for treating synucleinopathies

PendingEP4461362A2Organic active ingredientsNervous disorderThiazolePramipexole dihydrochloride monohydrate
The present invention describes the use of a NK1-antagonist, in combination with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to facilitate the treatment of a patient suffering from a synucleinopathy by enabling a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose to act without the typical adverse effects caused by pramipexole dihydrochloride monohydrate when administered alone.
Owner:ALTO NEUROSCIENCE INC

Bispecific antibody against alpha-syn / IGF1r and use thereof

The present disclosure relates to a bispecific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bispecific antibody for the prevention, treatment and / or diagnosis of synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.
Owner:ABL BIO INC

Variant rnai against alpha-synuclein

To provide RNAi molecules for treating neurodegenerative synucleinopathies that target expression of alpha-synuclein (SNCA).SOLUTION: An RNAi is provided comprising a first strand and a second strand, where a) the first strand and the second strand form a duplex; b) the first strand comprises a guide region, where the guide region comprises a nucleic acid having at least about 90% identity to the sequence 5'-ACUGCGCACAUUGGAACUGAG-3' (SEQ ID NO: 29); and c) the second strand comprises a non-guide region.SELECTED DRAWING: None
Owner:GENZYME CORP

Postbiotic compositions and methods of preparation and use

Provided herein are postbiotic compositions prepared using successive fermentation methods of specific bacteria and plant fiber material. Also provided herein are methods, including for the treatment or prevention of the disruption of gut microbiota, or dysbiosis, associated with an antibiotic treatment, chemotherapy treatment, or administration of a dysbiosis-causing medications or medical treatments, using said postbiotic compositions, or for improving responses and / or reducing complications to treatments such as antibiotics or chemotherapy. Such postbiotic compositions can also be used for the treatment or prevention of the disruption of the gut-brain axis, including to treat or prevent neurological diseases or disorders, such as synucleinopathies, including but not limited to Parkinson's disease.
Owner:POSTBIOTICS PLUS RESEARCH LLC